Ocular Therapeutix, Inc. (OCUL) Financials
OCUL Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 671.3 million | 151.3 million |
| March 31, 2026 | 732.5 million | 151.0 million |
| Dec. 31, 2025 | 808.1 million | 153.7 million |
| Sept. 30, 2025 | 410.9 million | 152.7 million |
OCUL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -70.6 million | 14.6 million |
| March 31, 2026 | -70.7 million | 15.6 million |
| Dec. 31, 2025 | -57.1 million | 11.4 million |
| Sept. 30, 2025 | -56.7 million | 11.7 million |
OCUL Net Income
No data available :(
OCUL Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 598.6 million | 72.8 million | 3.5 million |
| March 31, 2026 | 666.7 million | 72.1 million | 4.2 million |
| Dec. 31, 2025 | 737.1 million | 71.3 million | 5.6 million |
| Sept. 30, 2025 | 344.8 million | 70.6 million | 6.4 million |
OCUL Shares Outstanding
OCUL Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 3.4 million | 54.1 million | 39.4 million | 17.3 million |
| March 31, 2026 | 4.7 million | 66.2 million | 36.6 million | 16.6 million |
| Dec. 31, 2025 | 2.8 million | 50.8 million | 30.6 million | 13.0 million |
| Sept. 30, 2025 | 6.0 million | 52.4 million | 29.1 million | 13.1 million |
OCUL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 13.5 million | 2.0 million |
| March 31, 2026 | 10.8 million | 1.3 million |
| Dec. 31, 2025 | 13.3 million | 1.6 million |
| Sept. 30, 2025 | 14.5 million | 1.8 million |
OCUL Revenue by Segment
Graph available only for paid members. Upgrade to see it.
OCUL
Price: $10.04
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.47 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 567800
Ebitda: -14.6 millionMarket Capitalization: 2.2 billion